Quark, GF Securities invest $1.9 mln in Sitka Biopharma
Vancouver-based biotechnology company Sitka Biopharma has raised $1.9 million from Canadian life sciences venture capital firm Quark Venture and China’s GF Securities Co Ltd. Sitka is developing a nanoparticle platform to increase absorption of drugs in difficult-to-penetrate tissues. It will use the funds raised to complete work in advance of the initial Phase 1 clinical trials of STK-01, a lead product for treating bladder cancer. Founded in 2013 and led by President and CSO Michael Parr, Sitka is a spin off of The Centre for Drug Research and Development and University of British Columbia. It raised seed funding from Quark in 2016.
25 October 2018•4 mins read
